Over 3 Million Units of OTC Eye Drops Recalled Nationwide Over Contamination Risks, FDA Warns

Over 3 million units of over-the-counter eye drops have been recalled nationwide due to potential contamination risks that could harm vision, according to the U.S. Food and Drug Administration (FDA). The products, manufactured by K.C. Pharmaceuticals in California, are being pulled from shelves at major retailers including CVS, Walgreens, Kroger, and H-E-B, with lot codes listed on the FDA's website for consumer reference. The recall, classified as Class II by the FDA, indicates a temporary but reversible risk to users, though no illnesses or injuries have been reported to date.

The affected products include 1 million bottles of Dry Eye Relief Eye Drops, 590,000 bottles of Artificial Tears Sterile Lubricant Eye Drops, and other formulations, all sold in 0.5 fl oz bottles with best-before dates extending through May or October of this year. The FDA's Enforcement Report cited a "lack of assurance of sterility," suggesting the drops may be contaminated with bacteria or particles that could damage the eye. While the exact cause of the issue remains unclear, investigators suspect improper hygiene standards at the manufacturing facility may have played a role.

This recall echoes a similar crisis in 2023, when nearly 81 patients were sickened by contaminated eye drops produced in India. Those drops were found to harbor *Pseudomonas aeruginosa*, a bacteria resistant to standard antibiotics that can lead to blindness or even sepsis. "The stakes are high," said Dr. Lena Torres, an ophthalmologist in Texas. "Even a small amount of contamination can cause irreversible damage. Patients must take this warning seriously."

Consumers are advised not to use the recalled products and to return them to retailers for refunds. However, the FDA has not issued explicit guidance on whether the drops should be used until further notice. This ambiguity has sparked frustration among some users. "I bought these drops for dry eyes," said Sarah Nguyen, a 34-year-old teacher from Ohio. "Now I'm left wondering if I've been risking my vision all along."

The recall was first initiated in March and formally classified as Class II on March 31. The FDA's classification system defines Class II recalls as those involving products that may cause temporary, reversible harm, while Class I recalls are for serious risks like death or permanent injury. This distinction has led to criticism from consumer advocates, who argue the classification underplays the potential severity of eye infections.

In January 2024, another major recall occurred when Imprimis NJOF, a leading ophthalmic pharmacy, pulled nearly 2,000 boxes of prefilled syringes due to the presence of "glass-like particles." Such incidents have raised broader concerns about quality control in the eye care industry. Over 35% of Americans use over-the-counter eye drops annually, often for dryness, redness, or irritation from environmental factors like smoke.

Health officials warn that symptoms of contamination include persistent redness, pain, yellow discharge, light sensitivity, and blurred vision. Anyone experiencing these signs is urged to contact a doctor immediately. "This isn't just about the product—it's about trust," said FDA spokesperson Michael Carter. "We're working to ensure every drop meets sterility standards, but this incident shows how fragile that process can be."

As the recall continues, K.C. Pharmaceuticals has not issued a public statement, leaving consumers and regulators alike waiting for answers. For now, the message is clear: the eyes, once damaged, may never fully recover.